BofA analyst Alex Stranahan raised the firm’s price target on Moderna (MRNA) to $32 from $31 and keeps an Underperform rating on the shares after the company reported better-than-expected Q1 revenue of $389M. The company had a “solid” Q1, but growth depends on uptake and oncology data, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna: Solid Q1 Beat and EU Combo Vaccine Approval Offset by Regulatory Setbacks and Long Path to 2028 Breakeven, Justifying Hold Rating
- Morning Movers: Roblox and Western Digital sink after earnings
- Video: Apple rises after surprisingly strong revenue forecast
- Why Is Vanguard S&P 500 ETF (VOO) Up Today, 5/1/2026?
- Moderna reports Q1 EPS ($3.40), consensus ($3.88)